A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy men and women, ages 18 to 45 years

• Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory evaluations

• Women of child bearing potential are eligible for enrollment.

• Women must have a negative pregnancy test

Exclusion Criteria:

• Evidence of organ dysfunction

• Any significant acute or chronic medical illness

• Inability to: tolerate oral medications, be venipunctured